HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Canada Is Large Firms' CBD Test Market While US Weighs Allowing Sales

Executive Summary

Large beer and beverage firms partner with hemp cultivators to compete in fledgling US CBD-infused beverage market, which is estimated to reach $1.4bn sales by 2023. Many firms are working on R&D or have completed products and are waiting for a clear regulatory pathway from FDA before launch.

You may also be interested in...



US Wellness Market In 2019: Farm Bill Made Cultivating Cannabidiol Policy FDA's Main Course In Supplements

As HBW Insight looks back on notable US wellness market developments and events for the previous 12 months, we find that news in the CBD space from the FDA and the industry dominated the sector throughout 2019.

Coca-Cola Takes 'Things Go Better With Coke' Approach To Energy Drink Market

Coca-Cola plans to launch four-product energy drink line in the US in January. Drinks will taste like Coke Classic and feature two zero-calorie options to attract new consumers willing to try energy drinks but fear high-calorie drinks with unfamiliar ingredients.

As FDA Decides CBD Regulatory Path, Sales March On For Suppliers, Retailers

CV Sciences distributes PlusCBD Oil products to Vitamin Shoppe stores in 30 states and Puerto Rico, pushing its US distribution to more than 5,300 retail locations. Vitamin Shoppe began offering CBD products in March and has extended the sales to 390 stores.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

RS149125

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel